The new schizophrenia drug didn’t provide additional benefits when given on top of standard-of-care therapy, Bristol Myers Squibb announced Tuesday.

Bristol Myers Squibb said on Tuesday its drug Cobenfy failed to show a statistically significant difference in a keenly watched late-stage trial that would help expand its use, sending its shares ...

BMS is specifically testing Cobenfy as a treatment for Alzheimer’s disease psychosis — an indication area that, like schizophrenia, is rife with therapies that trigger difficult side effects.

This is the first new class of treatment for the psychiatric disorder since clozapine, the first atypical antipsychotic, was approved in 1989. Cobenfy is a combination of xanomeline and trospium.

The Food and Drug Administration approved Cobenfy on the strength of two encouraging company-sponsored five-week trials and other safety data.

Compared with placebo, xanomeline/trospium as an add-on to atypical antipsychotics has not reached the threshold for a statistically significant difference, top-line data show.

The U.S. FDA's approval Thursday of Bristol Myers Squibb's (NYSE:BMY) novel antipsychotic Cobenfy (xanomeline and trospium chloride) for schizophrenia could significant influence treatment of the ...

The FDA has approved Cobenfy, a new drug to treat people with schizophrenia that comes with fewer side effects.

The FDA has approved Bristol Myers Squibb’s new schizophrenia drug, Cobenfy, the first novel treatment for schizophrenia in over 70 years. Schizophrenia affects nearly 3 million U.S. adults, but ...

The drug, called Cobenfy, will be sold by Bristol Myers Squibb. It was developed by the biotech company Karuna Therapeutics, which Bristol acquired for $14 billion last year.

On Thursday, the FDA approved Bristol Myers Squibb & Co’s (NYSE:BMY) Cobenfy (xanomeline and trospium chloride, KarXT), an oral medication for schizophrenia in adults. BMO Capital analyst notes ...

The FDA approval of Bristol Myers Squibb's Cobenfy for schizophrenia could revolutionize treatment, but faces a competitive market of generic antipsychotics. Read more here.